In Japan, a nationwide mass screening system for neonatal metabolic diseases was established in 1977.
This system consisted of screening programs for five main congenital metabolic diseases, including phenylketonuria (PKU).
To evaluate the efficiency of the mass screening system, a cost-benefit analysis of the screening program for PKU (as a typical case in Japan) was carried out.
The costs of the detection and the treatment program were compared with the projected benefit (avoided costs) that results from prevention of the mental retardation associated with the disorders due to PKU.
Costs and benefits were discounted at an annual rate of 7%. Assuming that the incidence of PKU was 1/80,500 and the total number of infants screened was 1.2 million, net benefits for the screening program were $283,000, and the cost-benefit ratio was 1 : 2.5.
Mots-clés Pascal : Phénylcétonurie, Programme sanitaire, Campagne de masse, Dépistage, Nouveau né, Homme, Evaluation, Efficacité, Analyse avantage coût, Economie santé, Japon, Asie, Métabolisme pathologie, Aminoacidopathie, Système nerveux pathologie, Maladie héréditaire, Enzymopathie
Mots-clés Pascal anglais : Phenylketonuria, Sanitary program, Mass campaign, Medical screening, Newborn, Human, Evaluation, Efficiency, Cost benefit analysis, Health economy, Japan, Asia, Metabolic diseases, Aminoacid disorder, Nervous system diseases, Genetic disease, Enzymopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0591819
Code Inist : 002B22D05. Création : 09/06/1995.